The goal of the Clinical Research Core is to provide investigators in the SPORE high quality biospecimens as well as patient data from consented patients with glioma and to make these resources available for future studies. The services provided are: 1) to coordinate the collection, processing, storage, distribution and tracking of biospecimens including blood, throat swabs, urine and cerebrospinal fluid; 2) A: To extract clinical data from patient records and collect epidemiologic research information, with entry into the Neuro-Oncology Database for all newly-diagnosed glioma patients not on interventional clinical trials and B: to enroll controls who are age- gender- and race-matched to cases for Project 4; 3) to provide protocol-specific clinical data from patients enrolled in interventional clinical trials; and 4) to provide coordination and oversight of compliance with regulatory issues involving human subjects. This core will also serve as the interface with Mayo Clinic Cancer Center's shared resources including the Biospecimens Acquisition and Processing shared resource, the Clinical Research Office, and the Protocol Review and Monitoring System. In addition, this core will interact with the other cores of this SPORE application, including the Administrative Core by participating as a member of the Executive Committee, with the Biostatistics Core by joint development of data entry forms and quality assurance of clinical data, and with the Pathology Core by sharing the responsibilities for biospecimens review and utilization. These essential services provide support for specific aim 1 of project 1, specific aim 4 for project 2, essential biospecimens and data for all of the aims in projects 3 and 4, and one developmental project. Core utilization will include assisting in the recruitment of patients to studies, ensuring eligibility, informed consent, scheduling appropriate protocol tests and follow-up, obtaining clinical data and biospecimens from approximately 200 patients and 125 controls per year, entry of clinical trials data information according to Mayo Clinic Cancer Center policy set forth by the Clinical Research Office and Protocol Review and Monitoring System, and compliance with human subjects protection in keeping with the policies of the Mayo Clinic Cancer Center. Finally, this core will interface with the clinical research components of other Brain Tumor SPORE grantees, cancer centers and cooperative groups to facilitate multi-institutional clinical research arising out of national brain tumor research efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-05
Application #
7683219
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
5
Fiscal Year
2008
Total Cost
$258,893
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43
Vaubel, Rachael A; Caron, Alissa A; Yamada, Seiji et al. (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172-182
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:

Showing the most recent 10 out of 254 publications